SurgoCap Partners LP — TAIWAN SEMICONDUCTOR MANUFAC TSM: Quarterly 13F Position History
SurgoCap Partners LP has reported TAIWAN SEMICONDUCTOR MANUFAC (TSM) on 3 13F-HR filings in Pactolio's tracked window, first appearing in Q3 2025. As of Q1 2026, the position is sized at 1,108,073 shares ($374.5M market value, 12.50% of the equity book). Quarter-over-quarter share count change: 1,510 (-0.1%) .
- 1,108,073Shares Held (Latest Filing)
- $374.5MReported Market Value (Latest Filing)
- 12.50%Portfolio Weight (% of 13F Equity Book)
- 1,510Quarter-over-Quarter Share Change
- +$37.3MQuarter-over-Quarter Value Change
- 1,290,570Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 3 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 1,108,073 | 1,510 | -0.1% | $374.5M | 12.50% | $337.95 |
| Q4 2025 | 1,109,583 | 180,987 | -14.0% | $337.2M | 9.33% | $303.89 |
| Q3 2025 | 1,290,570 | — | — | $360.4M | 10.23% | $279.29 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did SurgoCap Partners LP first disclose a TSM position in 13F-HR filings?
SurgoCap Partners LP first reported TAIWAN SEMICONDUCTOR MANUFAC (TSM) on its 13F-HR filing for the period ending 2025-09-30 (Q3 2025). The position has appeared on 3 reported quarters within Pactolio's tracked window.
What was SurgoCap Partners LP's most recent quarter-over-quarter share-count change in TSM?
Between Q4 2025 and Q1 2026, SurgoCap Partners LP reduced its TSM position by 1,510 shares (-0.1%), leaving 1,108,073 shares at a market value of $374.5M.
Does the implied price-per-share represent SurgoCap Partners LP's cost basis in TSM?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.